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doi:10.1016/j.ijsu.2007.05.001Abstract Due to the increasing number of orthopaedic and cardiac procedures, these units
are considered as high-risk areas because of the potentially serious consequences of surgical
site infections (SSI), primarily caused by Staphylococcus aureus. The goal of this review
was to evaluate the impact of S. aureus on the incidence of SSI in these high risk wards.
Studies were identified by a search on the MEDLINE literature using the following mesh terms:
S. aureus, cardiac, orthopaedic, surgery, SSI. Beside, data from different surveillance systems
were also included. Overall, biological investigation was performed only on a small proportion
of identified SSIs. Of those identified, S. aureus represented the most common pathogen ac-
counting for approximately 20% of all SSIs. Of the 59,274 hip prostheses reported from the HE-
LICS surveillance network, S. aureus formed 48.6% of the pathogens (416 bacteria isolated).
Similarly, it represented 43.7% of pathogens after coronary artery bypass grafting. Although
S. aureus turned out to be the major pathogen, this work identifies the relative lack of knowl-
edge on the overall incidence of S. aureus infections and on the impact of this pathogenic
agent when taking into consideration the degree of wound contamination and category of SSI.
There is a need for more detailed information on the role of S. aureus in the burden of surgical
site infections and consequently how to establish multiple approach prevention programs.
ª 2007 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.78 77 70 31; fax: þ33 4 78 00
hoo.fr (M. Saadatian-Elahi).
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The number of surgical procedures being performed has
increased during the last 30 years due to advances in
surgical techniques, the increasing importance given tohalf of Surgical Associates Ltd.
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time expectancy. According to the latest available data
from USA, more than 4 million surgical procedures were
performed in 1999.1
Given that the overall number of surgical procedures is
increasing, the burden of surgical site infection (SSI) could be
more significant and should merit further attention. The
situation could be further aggravated due to the related
problems of antimicrobial resistance. SSIs comprise the third
most frequently reported nosocomial infection (NI), repre-
senting 14e16% of all hospital nosocomial infections.2,3 It has
been reported that about 2e5% of patients undergoing sur-
gerywill develop SSI.4e6 In addition to the increase of postop-
erative morbidity and mortality in surgical patients, SSIs are
also the cause of increased hospitalization costs by lengthen-
ing the mean postoperative hospitalization stay (LOS).7,8
Attributable mortality, morbidity and costs due to SSIs is of
particular importance in the elderly because of their gen-
eral, often fragile, health status, and the increasing number
of operations performed in this population.9
Surgical site infections are primarily caused by bacteria,
Staphylococcus aureus representing by far the most com-
mon pathogen found in surgical wounds.3 This pathogenic
agent is a Gram-positive spherical bacteria belonging to
the Staphylococci group. It can cause suppurative infec-
tions ranging from superficial skin lesions to deep-seated in-
fections. In orthopaedic and cardiac surgery, infections by
this agent cause severe life-threatening complications.
The purpose of the present work was to give an overview
of the existing epidemiological data on the incidence of
SSIs caused by S. aureus in orthopaedic and cardiac surgery.
Determinants of SSIs
The occurrence of SSI depends on several factors which
might be classified into the following subgroups: (i) host
derived factors such as advanced age,10e12 diabetes melli-
tus13e15 and malnutrition;13,16e18 (ii) the duration of the
surgical procedure;19,20 (iii) factors related to the prepara-
tion of the patient and operative sites.21
In addition to common risk factorsmentioned above, there
are specific factors according to the type of surgery. In
orthopaedic surgery, rheumatoid arthritis,22,23 psoriasis, im-
munosuppression or prior surgery at the site of prosthesis24,25
are associated with an increased risk of infection. In cardiac
surgery, the most significant risk factors are BMI > 40 kg/m2
(OR: 2.95, 95%CIZ 2.75e3.17), haemodialysis (OR: 2.12,
95% CIZ 1.91e2.35), cardiogenic shock (OR: 2.11, 95%CIZ
1.93e2.31), immunosuppressive treatment (OR: 1.51, 95%
CIZ 1.36e1.66), perfusion time 200 to 300 min (OR: 2.08,
95% CIZ 1.89e2.29), perfusion time >300 min (OR: 1.96,
95% CIZ 1.65e2.34), placement of an intra-aortic balloon
pump (OR: 1.53, 95% CIZ 1.44e1.63) and the presence of
three ormore anastomoses (OR: 1.28, 95% CIZ 1.19e1.39).26
Risk factors for SSIs due to S. aureus
Between 10% and 35% of healthy subjects are considered as
persistent nasal carriers of S. aureus,27 preoperative nasal
carriage of S. aureus being one of the major risk factors
for developing S. aureus wound infection. In orthopaedicsurgery, nasal carriage of S. aureus was the most important
risk factor for developing SSI with an RR of 8.9 (95%
CIZ 1.7e45.5).28 Similar results have been reported in
cardiac surgery.29e31 Compared to healthy subjects, some
clinical conditions may increase nasal carriage and conse-
quently lead to a higher risk of S. aureus SSI. In a study of
140 patients, 77% of diabetic subjects had nasal carriage
of S. aureus compared to 33% in non-diabetic patients.32
Likewise, patients treated by haemodialysis or peritoneal
dialysis were found to carry nasal S. aureus more frequently
than healthy subjects with rates ranging from 32% to 82% in
haemodialysis patients and from 23% to 67% in those with
peritoneal dialysis.33 Infection with human deficiency virus
(VIH) has also been associated with increased incidence of
S. aureus nasal carriage with an OR of 2.5 (95% CIZ 1.1e
5.6).34 The nasal carriage of S. aureus by the patient under-
going surgery is not the only source of infection. The asso-
ciation of its carriage by surgical personnel and the
subsequent SSI has also been recognized.35,36
S. aureus bacteraemia has also been associated with
higher risk of underlying SSI occurrence in several studies
which suggestedbloodculture is an accurate test for theearly
diagnosis of post-operative SSIs in febrile patients.37e39 In
a studyofpatients undergoing coronaryarterybypass grafting
(CABG), mediastinitis occurred in 46 of 60 (76.7%) patients
with positive blood cultures for S. aureus. The likelihood
ratio of developing mediastinitis in subjects with S. aureus
bacteraemiawas 25 (95%CI: 14.7e44.4) as compared to those
with negative blood culture for S. aureus.40
Importance of SSI in orthopaedic surgery
In the USA, orthopaedic surgical procedures are the fourth
most common type of operation after obstetrical, cardio-
vascular and digestive procedures respectively.41 In ortho-
paedic wards, SSIs represent approximately 20% of the
overall nosocomial infections,42 incidence rates differing
according to the type of surgery. Orthopaedic units are
classed as high-risk areas because of the potentially serious
consequences of infection particularly in patients with
prosthetics joints. One to five percent of prostheses be-
come infected, leading to significant morbidity and severe
functional impairment.
The extra cost attributable to SSIs has been estimated to
almost US$40,000/infected case.43 The mean length of ad-
ditional postoperative hospitalization stay ranged from 12
to over 20 days.43e45
Main SSIs following orthopaedic surgery
Prosthetic joint infections
Over the past few decades orthopaedic implant surgery has
become one of the most common types of orthopaedic
surgery. Total arthroplasty in itself is a relatively safe
procedure with incidence rates below 3%.46 Nevertheless, it
might lead to infections of the prosthetic material which
are related to high morbidity and often lead to severe func-
tional impairment. Prosthetic joint infections of the hip or
the knee are the major surgical complications after total
arthroplasty. Infection might occur within 6 months after
the surgical procedure (acute); within 2 years of the
240 M. Saadatian-Elahi et al.surgical procedure (sub-acute); or after 2 years of pain-free
mobility (chronic).47
Staphylococci (coagulase-negative staphylococci and S.
aureus) are the main causative agents in prosthetic joint
sepsis, representing more than 40% of all concerned micro-
organisms. Table 1 gives a summary of epidemiological dataTable 1 Incidence, morbidity and mortality rates of surgical si
Authors Country Type of surgery
(no. of operations
Coello et al.8 UK HPRO (24,002)
KPRO (11,785)
Thomas et al.48 Australia THR (1476)
TKR (1875)
NNIS49 USA HPRO (44,454)
KPRO (66,360)
LAM (73,846)
NINSS50 UK HPRO (16,809)
KPRO (15,792)
Hip (5364)
Hemiarthroplasty
CCLIN Sud-est51 France Orthopaedic overa
HPRO (1479)
KPRO (570)
HELICS52 Europe HPRO (59,274)
LAM (3142)
PREZIES53 The Netherlands Elective HPRO and
INCISO (1997e1999) France Bone with osteosy
Joint with prosthe
HPRO or KPRO
Osteosynthesis rem
Overall
SSI, surgical site infection; HPRO, hip prosthesis; LAM, laminectomy; K
cus aureus bacteraemia.
HELICS (Hospital in Europe, Link for InfectionControl through Surveillance
tries: Belgium, Finland, France, Germany, Greece, Lithuania, the Netheon the incidence and mortality rates of SSIs occurring after
orthopaedic implant surgery.
Osteomyelitis
Vertebral osteomyelitis is the major type of infection
observed after vertebral arthrodesis. Although it representste infections after orthopaedic surgery
)
Incidence
rate (%)
Mortality
rate (%)
SSI due to
S. aureus
3.1 1.8 Not stated
1.9 1.5
4.9 0.0 Unknown
5.15
RIC 0: 0.86 Not stated Not stated
RIC 1: 1.65
RIC 2, 3: 2.52
RIC 0: 0.88
RIC 1: 1.28
RIC 2, 3: 2.26
RIC 0: 0.88
RIC 1: 1.35
RIC 2, 3: 2.46
1.24 Not stated 49%
0.65
4.05
(3277) 2.01
ll (10,159) 0.9 Not stated 43%
2.5
0.5
RIC 0: 2.0 Not stated 48.6%
RIC 1: 3.8
RIC 2,3: 5.6
RIC 0: 0.8 Not stated Not stated
RIC 1: 1.7
RIC 2, 3: 1.9
KPRO 1994: 17.0 Not stated 22.2
1995: 10.0 0.0
1996: 5.0 16.7
1997: 3.0 25.0
1998: 1.0 Unknown
1999: 2.0 Unknown
nthesis 1.2 0.9 Not stated
sis 1.1 0.1
1.9 1.5
oval 1.0 0.4
1.4 0.9
PRO, knee prosthesis, RIC, risk index category; SAB, Staphylococ-
) is a Europeannetworkwhich includesover600hospitals in10coun-
rlands, Poland, Spain, UK, Northern Ireland, Scotland and Wales.
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ous and related to high morbidity and mortality. In studies
with microbiological data, S. aureus represented between
40% and 75% of the identified microorganisms.54e56
SSIs related to arthroscopic surgery
The use of arthroscopy in the diagnosis and treatment of joint
injuries is rising mainly because of the benefits of faster
recovery and lower costs for both the patient and the
healthcare system. The puncture wounds are small and the
recovery is easier compared to ‘‘open’’ surgery. Arthroscopy
is perceived as having low risk of SSI (0.01e0.48%), even if
infections do occur occasionally. Following two incidents of
arthroscopic infectious outbreaks in 1995 and1998e1999, two
caseecontrol studies were carried out at a 100-bed private
hospital in theUSA.57Of the 27 cases identified (10 for the first
period and 17 for the second period), the authors reported
that S. aureus was the major pathogenic agent (44%), fol-
lowed by Coagulase-negative Staphylococcus (30%). The ma-
jor risk factors associated with an increased risk of SSI were
intra-articular corticosteroid joint injection (OR: 9.3; 95%
CIZ 1.6e64.9) and preoperative razor shaving (pZ 0.03).
Importance of SSI in cardiac surgery
Cardiovascular operations represent the second most fre-
quent surgical procedures with more than 6 million opera-
tions carried out in the USA in 1999.1 SSI in cardiac
surgery patients is a serious complication leading to higher
morbidity, mortality and prolonged hospital stay. In addi-
tion, the financial burden of such infections on the health-
care system can be colossal, adding an extra cost of almost
US$40,000 per SSI.58
Main types of cardiac surgery involve cardiovascular im-
plants, cardiac transplantation, and the increasingly common
high-tech procedure of coronary artery bypass grafting
(CABG). Patients undergoing such surgery have an increased
risk of developing SSI because of the presence of multipleTable 2 Summary of incidence of SSI after cardiac surgery
Authors Country Type of surgery N
Lepelletier et al.59 France All
Immer et al.60 Switzerland Sternotomy
Upton et al.61 New Zealand Median sternotomy
Tang et al.62 Canada CABG 3
Crabtree et al.63 USA CABG
Sharma et al.64 USA CABG
Harrington et al.65 Australia CABG
C-CLIN sud-est51 France Overall cardiac surgery
NNIS49 USA CABG 1
HELICS52 Europe CABG 2
Gummert et al.66 Switzerland Sternotomy
Baskett et al.67 Canada Sternotomy
Borger et al.68 Canada CABG
S.A, Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcu
nal wound infection.wounds (chest and lower extremity incision) and the use of
post-operative invasive devices (i.e. pulmonary catheter).
S. aureus is the most common pathogen involved in the
epidemiology of SSI after cardiac surgery (Table 2). Other
major pathogens include S. epidermidis, Enterococcus
spp. and Gram-negative organisms.30
Main SSIs following cardiac surgery
Mediastinitis
Mediastinitis or deep sternal wound infection (DSWI) is
a rare but major complication after median sternotomy
procedure, with incidence rates of 1e3%, but a mortality
rate of almost 15%. The adjusted hazard ratio of long-term
mortality for patients with DSWI was reported to be 2.44
(95% CIZ 1.51e392).69 Tracheostomy has been shown to be
associated with an increased risk of DWSA after median
sternotomy. In a recent retrospective review of 16,277 ster-
notomies, the rate of DWSA was 3.4% in patients with tra-
cheostomy compared to 0.8% in patients without
tracheostomy. The OR of developing DWSA after tracheos-
tomy was 5.78 (95% CIZ 4.29e7.80).70 Similar results
have already been reported by Curtis and collaborators
who reviewed more than 6000 CABG.71
Emergency CABG was associated with a 10-fold increase
(OR: 10.9; 95% CIZ 2.7e44.7) in DSWI in a retrospective
analysis of 863 patients.72
Endocarditis
Endocarditis is defined as an infection of the endocardial
surface of the heart, which may include one or more heart
valves, the mural endocardium, or a septal defect. The
heart valves affected by the infection are primarily the
mitral (28e45%) and aortic valves (5e36%). The incidence
of infective endocarditis is low (less than 2%). However,
surgical advances that permit more patients to undergo
heart valve replacement will increase the extent of this
problem. The mortality rate increases with increased age,o. of. operations No. of. SSI (%) SSI due to S.A or MRSA
1268 38 (3) Major pathogen
5690 55 (0.97) 41.8% S.A
5176 70 (1.35) 82% S.A
16% MRSA
0102 232 (0.77)
4004 73 (1.8)
3443 55(1.5) 49% S.A
4474 349 (7.8) 32% MRSA
1050 24 (2.3) 38.9% S.A
5473 663 (4.3) Not stated
8453 768 (2.7) 43.7%
9303 134 (1.44)
DSWI
9771 24 (0.25) Not stated
8050 67 (0.83) 42%
DSWI
s aureus; CABG, coronary artery bypass grafting; DSWI, deep ster-
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gestive heart failure, central nervous system complica-
tions, and underlying disease. The morbidity, mortality and
costs of these infections are higher than other NI, the case-
fatality rate ranging from 10% to 30%.73
Infective endocarditis can occur after valve replacement
or pacemaker implant. Infective endocarditis on pace-
maker leads has been the subject of a synthetic review
by Meune and collaborators73 who selected 294 (183 men
and 108 women) cases from the literature using the Duke
criteria.74 The main risk factors for developing endocarditis
on pacemaker leads have been found to be diabetes, neo-
plasia, and corticoid treatments. Acute (<2 months after
the surgery), sub-acute (>2 and <12 months) and chronic
infective endocarditis (>12 months) represented 28%, 40%
and 32% of all infections respectively. Microbiological
analysis showed that S. aureus was the most abundant
microorganism isolated in acute infections (40%) while
Staphylococcus epidermidis was the main aetiological
germ in sub-acute and chronic endocarditis (48.5%).
Prosthetic valve endocarditis (PVE) is also a rare but
serious complication after cardiac surgery. The microbial
aetiology is dominated by S. epidermidis followed by S.
aureus accounting for about 30% and 20% of cases, respec-
tively75, but S. aureus is associated with higher mortality
rates. In a recent study carried out using the International
Collaboration on Endocarditis merged database (ICE-MD),
the overall mortality among 61 patients with PVE due to
S. aureus was 47.5%.76Discussion
Studies with microbiological data have shown that S. aureus
is the major pathological agent involved in the aetiology of
surgical site infections in orthopaedic and cardiac surgery.
Infection by S. aureus can lead to more serious complica-
tions in orthopaedic and cardiac procedures which use im-
planted biomaterials. S. aureus has the capacity to
produce biofilms or slime layers of glycocalyx which form
large microcolonies and adhere to the prosthetic material.
These biofilms are less affected by antibiotics and ingestion
by neutrophils.77,78 They might consequently cause chronic
infections associated with significant morbidity, pain, loss
of function and death. Infection by S. aureus might also
be influenced by host genetic factors. Recognition of micro-
bial antigens during infection is mediated by Toll-like re-
ceptors (TLRs), which are transmembrane proteins that
initiate the innate immune response to infection. Several
TLRs share a common intracellular domain with cytokine re-
ceptors IL-1RI and IL-18R. IL-1RI deficient mice have been
shown to be highly susceptible to S. aureus infection.79,80
MyD88, the cytoplasmic adaptor molecule for the signalling
of cellular response, as well as the interleukin-1 receptor-
associated kinase-1 (IRAK-1) are also essential for protec-
tion against S. aureus infection.80,81
Integration of determinants of infection in prevention
programs is important for the control of SSI, of which nasal
carriage of S. aureus is one of the major risk factors. A diag-
nostic test to detect nasal carriage followed by elimination
of nasal S. aureus seems therefore to be an efficient scheme
to adopt. Mupirocin is the most common compound used instudies of nasal prophylaxis. In a recent randomized pla-
cebo-controlled clinical trial study of 3864 patients undergo-
ing general, gynaecologic, neurologic or cardiothoracic
surgery, the OR of S. aureus infection in patients treated
with intranasal mupirocin compared to placebo was 0.45
(95% CIZ 0.25e0.92).82 Other authors have also reported
significantly lower incidences in subjects undergoing cardiac
surgery with perioperative mupirocin nasal ointment than in
controls.83,84 The use of mupirocin in orthopaedic surgery
was associated with a non-significant decrease of S. aureus
infection (RR: 0.19, 95% CIZ 0.02e1.62)85 indicating that
mupirocin has no effect on the incidence of SSI by S. aureus,
but other authors have provided conflicting results.86 S. au-
reus bacteraemia has also been associatedwith an increased
risk of infection.37e40 Prevention programmes should there-
fore include systematic detection of such infections and
consider postponement of the surgical procedure if neces-
sary and feasible. Transient bacteraemia due to dental
treatment has been associated with late prosthetic valve en-
docarditis and late prosthetic joint infection. Appropriate
antibiotic prophylaxis during dental intervention might be
of importance in reducing chronic infections in a high-risk
population with prosthetic materials.87
The treatment of S. aureus SSIs is further complicated by
the emerging problem of multidrug-resistant strains and in
particular methicillin-resistant S. aureus (MRSA), which
represent the dominant cause of S. aureus hospital-ac-
quired infections. The problem of MRSA SSI is of particular
importance in orthopaedic and cardiac surgery because of
the potentially serious consequences of such infections. In
a cohort study of subjects undergoing cardiac, orthopaedic
and neurological surgery, 165 patients developed SSI meth-
icillin-sensitive S. aureus SSI (MSSA SSI) and 121 had MRSA
SSI. The adjusted odds ratio of 90-day mortality rate was
3.4 (95% CIZ 1.5e7.2) in MRSA SSI patients as compared
to patients with MSSA SSI.88 The extensive use of antibiotics
is the primary cause of S. aureus resistance. Improvements
in the timing of initial administration, the appropriate
choice of antibiotic agents, and shorter duration of antibi-
otic administration can therefore be considered as key
points in reducing such resistance.
Routine surveillance is the basic element for successful
identification of infections that cause high morbidity and
mortality and for reducing SSIs rates.53,89 Regular feedback
of the data to surgeons and infection control activities car-
ried out in parallel to surveillance has been shown to have
an additional effect in lowering SSI rates.90,91 The results of
surveillance can be further completed by inter-hospital com-
parisons using benchmarking methods. Such comparison is
currently facilitated by standardized nationwide surveil-
lance networks which have recently been set up in several
countries. Post-discharge surveillance is an important issue
particularly in surgical wards. With the increasing trend for
ambulatory surgery over the past decade, more SSIs are oc-
curring after the patient has left hospital.3,92e95 Developing
post-discharge surveillance is therefore essential for the
achievement of reliable SSI rates and for a better validity
of inter-hospital comparisons. Telephone surveys or
patient-completed questionnaires have been used for
out-patient surveillance.96,97 However, the validity of the
data obtained needs to be proved by prospective studies
comparing differentmethods of post-discharge surveillance.
S. Aureus in cardiac and orthopaedic surgery 243In summary, S. aureus is the major pathological agent of
surgical site infection. Numerous studies have investigated
and identified the risk factors which might contribute to
higher incidence of SSI related S. aureus. However, there
is still relatively little information in the literature on the
impact of this pathogenic agent when taking into consider-
ation the degree of the wound contamination (clean, clean-
contaminated, contaminated, and dirty) and the category
of SSI (superficial, deep, and organ-space). Further pro-
spective biochemical epidemiologic studies are warranted
for a better understanding of the role of S. aureus in the
burden of surgical site infections and consequently in the
establishment of multiple-approach prevention programs.
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